share_log

康寧傑瑞製藥-B：截至2023年12月31日止年度年度業績公告

ALPHAMAB-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 28 09:50
Summary by Moomoo AI
康寧傑瑞生物製藥（「本公司」）公佈截至2023年12月31日止年度的經審核綜合業績。報告顯示，公司收入由2022年的人民幣166,845千元增加至2023年的人民幣218,774千元，毛利由人民幣122,638千元增至人民幣163,537千元。然而，研發開支及行政開支分別為人民幣407,524千元及人民幣79,338千元，導致公司年內虧損為人民幣210,593千元，較2022年的虧損人民幣325,722千元有所減少。公司於報告期間在藥物產品管線及業務經營方面取得重大進展，包括KN046、KN026等多個臨床試驗。此外，公司於2023年2月完成先舊後新配售及認購，收取所得款項淨額約為376.2百萬港元。公司股東及潛在投資者應審慎行事，並注意到公司不能保證其將能夠成功開發或最終成功營銷其核心產品KN046及KN026。
康寧傑瑞生物製藥（「本公司」）公佈截至2023年12月31日止年度的經審核綜合業績。報告顯示，公司收入由2022年的人民幣166,845千元增加至2023年的人民幣218,774千元，毛利由人民幣122,638千元增至人民幣163,537千元。然而，研發開支及行政開支分別為人民幣407,524千元及人民幣79,338千元，導致公司年內虧損為人民幣210,593千元，較2022年的虧損人民幣325,722千元有所減少。公司於報告期間在藥物產品管線及業務經營方面取得重大進展，包括KN046、KN026等多個臨床試驗。此外，公司於2023年2月完成先舊後新配售及認購，收取所得款項淨額約為376.2百萬港元。公司股東及潛在投資者應審慎行事，並注意到公司不能保證其將能夠成功開發或最終成功營銷其核心產品KN046及KN026。
Corning Jerry Biopharmaceuticals (the “Company”) announces audited consolidated results for the year ended December 31, 2023. The report showed that the company's revenue increased from RMB166,845 thousand in 2022 to RMB218,774 thousand in 2023, and gross profit increased from RMB122,638 thousand to RMB163,537 thousand. However, R&D expenses and administrative expenses of RMB407,524 thousand and RMB79,338 thousand, respectively, resulted in a loss of RMB210,593 thousand for the year, a decrease from RMB325,722 thousand in 2022. The Company made significant progress in its drug product pipeline and business operations during the reporting period, including several clinical trials, including KN046, KN026. In addition, the Company completed both old and new sales and subscriptions in February 2023 and received a net proceeds of approximately HK$376.2 million. Shareholders and potential investors should exercise caution and note that the Company cannot guarantee that it will be able to successfully develop or ultimately successfully market its core products KN046 and KN026.
Corning Jerry Biopharmaceuticals (the “Company”) announces audited consolidated results for the year ended December 31, 2023. The report showed that the company's revenue increased from RMB166,845 thousand in 2022 to RMB218,774 thousand in 2023, and gross profit increased from RMB122,638 thousand to RMB163,537 thousand. However, R&D expenses and administrative expenses of RMB407,524 thousand and RMB79,338 thousand, respectively, resulted in a loss of RMB210,593 thousand for the year, a decrease from RMB325,722 thousand in 2022. The Company made significant progress in its drug product pipeline and business operations during the reporting period, including several clinical trials, including KN046, KN026. In addition, the Company completed both old and new sales and subscriptions in February 2023 and received a net proceeds of approximately HK$376.2 million. Shareholders and potential investors should exercise caution and note that the Company cannot guarantee that it will be able to successfully develop or ultimately successfully market its core products KN046 and KN026.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more